What Is Thymosin Alpha-1?

Thymosin alpha-1 is a synthetic version of a 28-amino-acid peptide first isolated from calf thymus tissue in 1977. Under the generic name thymalfasin, it has been licensed as a drug in dozens of countries outside the United States — but the FDA has never approved it for any use, and in December 2024 a federal advisory committee voted against giving it even the narrower status of an approved compounding ingredient.

What thymosin alpha-1 is

Thymosin alpha-1 is a heat-stable, highly acidic peptide made of 28 amino acid residues. Researchers led by Allan Goldstein first determined its sequence from calf thymus extract in 1977, identifying it as one of several biologically active polypeptides present in a thymus preparation known as thymosin fraction 5. That 1977 paper, published in the Proceedings of the National Academy of Sciences, proposed the naming system still used today for the broader family of thymosin peptides, of which thymosin alpha-1 is only one member — a different peptide from thymosin beta-4, the one more often discussed in connection with the research compound TB-500.

The version studied and sold today is synthetic, made to match that original sequence rather than extracted from animal tissue. Goldstein's own later writing describes it as "a synthetic version of a thymic-derived biological response modifier," a description that points to how it has mostly been studied: not as a replacement for a missing hormone, but as a compound that nudges various parts of the immune system — a role distinct from, and far less specific than, an approved drug's labeled mechanism of action.

How it moved from a 1977 isolation to a licensed drug

Goldstein's group kept working on the peptide for decades afterward. A 2007 historical overview by immunologist Enrico Garaci, a longtime collaborator, describes the research direction that followed: studies combining thymosin alpha-1 with cytokines and chemotherapy, laboratory findings that it increased expression of MHC class I molecules and Toll-like receptors on immune cells, and pilot clinical trials in patients with hepatitis C and cancer that grew out of that laboratory work.

That clinical program eventually produced a licensed product. A 2009 review co-authored by Goldstein states that thymosin alpha-1 "is approved in over 35 countries for the treatment of hepatitis B and C, and as an immune stimulant and adjuvant," and that it was in late-stage clinical testing in the United States and Europe for hepatitis C and stage IV melanoma at the time. That U.S. and European testing never produced an approval; as discussed below, the compound remains unapproved by the FDA to this day.

What the largest trial of it actually found

The most rigorous test of thymosin alpha-1's clinical effect is also one of the most recent. The TESTS trial, published in The BMJ in January 2025, was a multicenter, double-blinded, placebo-controlled phase 3 trial run across 22 centers in China between 2016 and 2020. It enrolled 1,106 adults with sepsis, randomly assigning them to subcutaneous thymosin alpha-1 or placebo every 12 hours for up to seven days.

The result was unambiguous: 28-day all-cause mortality was 23.4% in the thymosin alpha-1 group and 24.1% in the placebo group, a difference the researchers describe as showing "no clear evidence" that the drug reduces mortality in sepsis. No secondary or safety outcome differed significantly between the two groups either. A prespecified subgroup analysis did turn up statistically significant differences by age and by diabetes status, the kind of subgroup finding that trial statisticians conventionally treat as hypothesis-generating rather than a confirmed effect, since testing many subgroups raises the odds that some will appear significant by chance. Worth noting for anyone weighing the result: several of the trial's authors disclosed grants or consulting fees from SciClone Pharmaceuticals, a company the trial's own conflict-of-interest statement connects to thymalfasin's commercial development.

What the COVID-19 studies found — and why they disagree

No randomized trial has tested thymosin alpha-1 specifically for COVID-19; the published evidence there is entirely observational, and it points in different directions depending on which cohort is being examined.

A retrospective review of 76 severe COVID-19 cases at two Wuhan hospitals, published in Clinical Infectious Diseases in 2020, reported lower mortality among patients who received thymosin alpha-1 than among those who didn't (11.11% versus 30.00%). The same research group also reported that the drug was associated with recovery of T-cell counts and reduced markers of T-cell exhaustion in these patients.

A larger retrospective cohort told a different story. A multicenter study across five hospitals in Hubei province, covering 2,282 patients (306 of whom received thymosin alpha-1), found a higher crude non-recovery rate in the treated group (21.2% versus 14.6%) and higher crude in-hospital mortality (20.2% versus 13.7%). After statistical adjustment for other factors, the association between thymosin alpha-1 and non-recovery remained significant on its own, though it weakened to non-significance once each patient's peak severity score was added to the model — a sign that sicker patients were simply more likely to be given the drug in the first place, which is a common distortion in observational treatment comparisons rather than necessarily evidence of harm.

Where it's licensed, and where it isn't

Outside the United States, thymosin alpha-1 has a real regulatory footprint: Goldstein's 2009 review puts licensed approval for hepatitis B and C, plus use as an immune stimulant and adjuvant, at more than 35 countries. Inside the United States, it has none. The FDA has never approved thymosin alpha-1 for any indication.

That gap was tested again in December 2024, when the FDA's Pharmacy Compounding Advisory Committee considered whether thymosin alpha-1 should be added to the Section 503A Bulks List — the list of substances compounding pharmacies may legally use even without FDA approval of the finished drug. According to the committee's own final summary minutes, members voted 17 to 4 against placing thymosin alpha-1 (in both its free-base and acetate forms) on that list, a decision covering a use list that spanned hepatitis B and C, HIV, COVID-19, several cancers, sepsis and a handful of other conditions. The minutes record that several members who voted no said there was no compelling evidence demonstrating clinical effectiveness and safety in the uses under review, while some of the four who voted yes said the substance should remain accessible as an option.

What's known versus what isn't

What's well established: the 1977 isolation and sequence, the compound's decades-long licensed use abroad for hepatitis B and C, and the existence of one large, rigorous, randomized trial — in sepsis, not any of the conditions it's licensed for abroad — that found no mortality benefit.

What's thin or unsettled: every published COVID-19 study is observational, the two largest disagree with each other, and the committee that most recently and systematically reviewed the human evidence across all proposed uses — not just sepsis or COVID-19 — concluded the evidence for effectiveness and safety did not support even the lower bar of compounding access. No large randomized trial has tested thymosin alpha-1 against any of the conditions for which it carries approval abroad.

What this means for researchers

Thymosin alpha-1 shows how far a licensed-abroad status and a rigorous domestic trial can diverge from each other. It has carried drug approvals in dozens of countries for decades, yet the one placebo-controlled trial run at the scale regulators consider dispositive — more than a thousand patients, properly randomized, double-blinded — found no benefit on the outcome it measured. Neither fact cancels the other out; they describe different evidence for different questions, and conflating "approved somewhere" with "proven effective for X" is exactly the kind of error that a published trial record is meant to prevent.

For anyone tracking a compound through exactly this kind of mixed regulatory history, the FDA's own advisory committee minutes and bulk drug substance lists are more reliable than secondary summaries of them, and the same caution applies to treating a single observational cohort — in either direction — as settled. The Torrey Labs learning library and the journal's explainer on HHS's interim peptide compounding policy cover the broader 503A compounding framework this compound was weighed against.